Tucker Joseph Edward 4/A
4/A · Enveric Biosciences, Inc. · Filed Oct 12, 2021
Insider Transaction Report
Form 4/AAmended
Tucker Joseph Edward
DirectorCHIEF EXECUTIVE OFFICER
Transactions
- Award
Common Warrants
2021-09-16+13,290→ 13,290 total(indirect: See footenote)Exercise: $2.82From: 2021-09-16Exp: 2023-09-16→ Common Stock (13,290 underlying) - Award
Common Stock
2021-09-16+691,083→ 691,083 total(indirect: See footnote) - Award
Common Warrants
2021-09-16+531,602→ 531,602 total(indirect: See footenote)Exercise: $0.94From: 2021-09-16Exp: 2025-05-26→ Common Stock (531,602 underlying) - Award
Common Warrants
2021-09-16+132,901→ 132,901 totalExercise: $0.94From: 2021-09-16Exp: 2025-05-26→ Common Stock (132,901 underlying)
Footnotes (7)
- [F1]Pursuant to an Amalgamation Agreement, dated May 24, 2021 (the "Amalgamation Agreement"), by and among Enveric Biosciences, Inc. (the "Company"), 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), ("HoldCo"), 1306436 B.C. Ltd., ("Purchaser"), and MagicMed Industries Inc. ("MagicMed"), upon the completion of the Amalgamation, the shareholders of MagicMed received shares of common stock of the Company equal to the product of 0.265801 (the "Exchange Ratio") multiplied by the number of MagicMed shares held by each such MagicMed shareholder.
- [F2]Received in exchange for 2,600,000 shares of common stock of MagicMed pursuant to the Amalgamation Agreement.
- [F3]Held indirectly through the Tucker 2020 Family Trust, a trust benefiting (but not controlled by) Dr. Tucker and his family.
- [F4]Pursuant to the Amalgamation Agreement, following the effective time of the Amalgamation, each holder of an outstanding MagicMed warrant is entitled to receive upon exercise of such MagicMed warrant that number of Company shares which the holder would have been entitled to receive as a result of the Amalgamation if, immediately prior to the Amalgamation, such holder had exercised the MagicMed warrants.
- [F5]The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 500,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.
- [F6]The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 2,000,000 shares of common stock of MagicMed with an exercise price of $0.25 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.
- [F7]The Reporting Person held MagicMed warrants immediately prior to the effective time of the Amalgamation to acquire 50,000 shares of common stock of MagicMed with an exercise price of $0.75 per share. At the effective time of the Amalgamation, the Reporting Person is entitled to receive shares of Company common stock upon exercise of the MagicMed warrants.